Targeting mutant p53 in cancer: a long road to precision therapy

FEBS Journal

Volumn 284, Issue 6, 2017, Pages 837-850

  Mantovani, Fiamma ^a,b   Walerych, Dawid ^a,c   Sal, Giannino Del ^a,b  

^a Laboratorio Nazionale CIB LNCIB   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

gain of function; missense mutant p53; oncogenic signaling; precision therapy; tumor environment

Indexed keywords

PROTEIN P53; MICRORNA; MUTANT PROTEIN; TP53 PROTEIN, HUMAN;

CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL FUNCTION; CELL METABOLISM; CHROMATIN; CYTOPLASM; GAIN OF FUNCTION MUTATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASM; MISSENSE MUTATION; NONHUMAN; PERSONALIZED MEDICINE; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICRORNAS; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; NEOPLASMS; PRECISION MEDICINE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85006386995     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13948     Document Type: Review

References (86)

1. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA et al. (2013) Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339.
2. Walerych D, Napoli M, Collavin L & Del Sal G (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33, 2007–2017.
3. Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M & Moll UM (2015) Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523, 352–356.
4. Walerych D, Lisek K & Del Sal G (2015) Mutant p53: one, no one, and one hundred thousand. Front Oncol 5, 289.
5. Parrales A & Iwakuma T (2015) Targeting ONCOGENIC Mutant p53 for cancer therapy. Front Oncol 5, 288.
6. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148, 244–258.
7. Weissmueller S, Manchado E, Saborowski M, Morris JP 4th, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T et al. (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157, 382–394.
8. Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A et al. (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525, 206–211.
9. Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C et al. (2016) Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol 18, 897–909.
10. Bykov VJ & Wiman KG (2014) Mutant p53 reactivation by small molecules makes its way to the clinic. FEBS Lett 588, 2622–2627.
11. Muller PA & Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15, 2–8.
12. Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC & Bargonetti J (2015) Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proc Natl Acad Sci USA 112, E1220–E1229.
13. Restle A, Farber M, Baumann C, Bohringer M, Scheidtmann KH, Muller-Tidow C & Wiesmuller L (2008) Dissecting the role of p53 phosphorylation in homologous recombination provides new clues for gain-of-function mutants. Nucleic Acids Res 36, 5362–5375.
14. Song H, Hollstein M & Xu Y (2007) p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol 9, 573–580.
15. Liu DP, Song H & Xu Y (2010) A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 29, 949–956.
16. Gamell C, Jan Paul P, Haupt Y & Haupt S (2014) PML tumour suppression and beyond: therapeutic implications. FEBS Lett 588, 2653–2662.
17. Imbriano C, Gurtner A, Cocchiarella F, Di Agostino S, Basile V, Gostissa M, Dobbelstein M, Del Sal G, Piaggio G & Mantovani R (2005) Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol 25, 3737–3751.
18. Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G & Haupt Y (2009) Promyelocytic leukemia protein is required for gain of function by mutant p53. Cancer Res 69, 4818–4826.
19. Strano S, Munarriz E, Rossi M, Cristofanelli B, Shaul Y, Castagnoli L, Levine AJ, Sacchi A, Cesareni G, Oren M et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275, 29503–29512.
20. Gaiddon C, Lokshin M, Ahn J, Zhang T & Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21, 1874–1887.
21. Strano S, Fontemaggi G, Costanzo A, Rizzo MG, Monti O, Baccarini A, Del Sal G, Levrero M, Sacchi A, Oren M et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277, 18817–18826.
22. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387–402.
23. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V et al. (2009) A mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87–98.
24. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A et al. (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20, 79–91.
25. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S et al. (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16, 357–366.
26. Zanconato F, Cordenonsi M & Piccolo S (2016) YAP/TAZ at the roots of cancer. Cancer Cell 29, 783–803.
27. Di Agostino S, Sorrentino G, Ingallina E, Valenti F, Ferraiuolo M, Bicciato S, Piazza S, Strano S, Del Sal G & Blandino G (2016) YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins. EMBO Rep 17, 188–201.
28. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y et al. (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci USA 111, E89–E98.
29. Li Z, Wang Y, Zhu Y, Yuan C, Wang D, Zhang W, Qi B, Qiu J, Song X, Ye J et al. (2015) The Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancer. Mol Oncol 9, 1091–1105.
30. Taccioli C, Sorrentino G, Zannini A, Caroli J, Beneventano D, Anderlucci L, Lolli M, Bicciato S & Del Sal G (2015) MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells. Oncotarget 6, 38854–38865.
31. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA et al. (2014) Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54, 960–974.
32. Wang W, Xiao ZD, Li X, Aziz KE, Gan B, Johnson RL & Chen J (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 17, 490–499.
33. Zhang C, Liu J, Liang Y, Wu R, Zhao Y, Hong X, Lin M, Yu H, Liu L, Levine AJ et al. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4, 2935.
34. Rodriguez OC, Choudhury S, Kolukula V, Vietsch EE, Catania J, Preet A, Reynoso K, Bargonetti J, Wellstein A, Albanese C et al. (2012) Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle 11, 4436–4446.
35. Pollak MN (2012) Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2, 778–790.
36. Muti P, Berrino F, Krogh V, Villarini A, Barba M, Strano S & Blandino G (2009) Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle 8, 2661.
37. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D & Jacks T (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847–860.
38. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861–872.
39. Terzian T, Suh YA, Iwakuma T, Post SM, Neumann M, Lang GA, Van Pelt CS & Lozano G (2008) The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev 22, 1337–1344.
40. Blagosklonny MV, Toretsky J, Bohen S & Neckers L (1996) Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc Natl Acad Sci USA 93, 8379–8383.
41. Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F & Moll UM (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 9, 577–588.
42. Li D, Marchenko ND & Moll UM (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18, 1904–1913.
43. Suh YA, Post SM, Elizondo-Fraire AC, Maccio DR, Jackson JG, El-Naggar AK, Van Pelt C, Terzian T & Lozano G (2011) Multiple stress signals activate mutant p53 in vivo. Cancer Res 71, 7168–7175.
44. Nguyen TA, Menendez D, Resnick MA & Anderson CW (2014) Mutant TP53 posttranslational modifications: challenges and opportunities. Hum Mutat 35, 738–755.
45. Girardini JE, Walerych D & Del Sal G (2014) Cooperation of p53 mutations with other oncogenic alterations in cancer. Subcell Biochem 85, 41–70.
46. Zerbini LF, Wang Y, Correa RG, Cho JY & Libermann TA (2005) Blockage of NF-kappaB induces serine 15 phosphorylation of mutant p53 by JNK kinase in prostate cancer cells. Cell Cycle 4, 1247–1253.
47. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G & Di Agostino S (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10, 4330–4340.
48. Mantovani F, Zannini A, Rustighi A & Del Sal G (2015) Interaction of p53 with prolyl isomerases: healthy and unhealthy relationships. Biochim Biophys Acta 1850, 2048–2060.
49. Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, Nuzzo S, Tuscano A, Eterno V, Benvenuti F, et al. (2014) Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med 6, 99–119.
50. Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You MH, Yao Y, Kondo A et al. (2015) Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nat Med 21, 457–466.
51. Connolly RM, Nguyen NK & Sukumar S (2013) Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res 19, 1651–1659.
52. Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T & Kroemer G (2008) Mutant p53 protein localized in the cytoplasm inhibits autophagy. Cell Cycle 7, 3056–3061.
53. Frank AK, Pietsch EC, Dumont P, Tao J & Murphy ME (2011) Wild-type and mutant p53 proteins interact with mitochondrial caspase-3. Cancer Biol Ther 11, 740–745.
54. Chee JL, Saidin S, Lane DP, Leong SM, Noll JE, Neilsen PM, Phua YT, Gabra H & Lim TM (2013) Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9. Cell Cycle 12, 278–288.
55. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P & Moll UM (2003) p53 has a direct apoptogenic role at the mitochondria. Mol Cell 11, 577–590.
56. Zhuang J, Wang PY, Huang X, Chen X, Kang JG & Hwang PM (2013) Mitochondrial disulfide relay mediates translocation of p53 and partitions its subcellular activity. Proc Natl Acad Sci USA 110, 17356–17361.
57. Wang PY, Ma W, Park JY, Celi FS, Arena R, Choi JW, Ali QA, Tripodi DJ, Zhuang J, Lago CU et al. (2013) Increased oxidative metabolism in the Li-Fraumeni syndrome. N Engl J Med 368, 1027–1032.
58. Vyas S, Zaganjor E & Haigis MC (2016) Mitochondria and cancer. Cell 166, 555–566.
59. Nakagawa K, Sasaki Y, Kato S, Kubodera N & Okano T (2005) 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26, 1044–1054.
60. Wang SH, Koenig RJ, Giordano TJ, Myc A, Thompson NW & Baker JR Jr (1999) 1Alpha,25-dihydroxyvitamin D3 up-regulates Bcl-2 expression and protects normal human thyrocytes from programmed cell death. Endocrinology 140, 1649–1656.
61. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E et al. (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17, 273–285.
62. Muller PA, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P et al. (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327–1341.
63. Muller PA, Trinidad AG, Timpson P, Morton JP, Zanivan S, van den Berghe PV, Nixon C, Karim SA, Caswell PT, Noll JE et al. (2013) Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion. Oncogene 32, 1252–1265.
64. Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E et al. (2009) The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol 16, 1086–1093.
65. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, Lane DP & Callen DF (2011) Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2, 1203–1217.
66. Yeudall WA, Vaughan CA, Miyazaki H, Ramamoorthy M, Choi MY, Chapman CG, Wang H, Black E, Bulysheva AA, Deb SP et al. (2012) Gain-of-function mutant p53 upregulates CXC chemokines and enhances cell migration. Carcinogenesis 33, 442–451.
67. Cooks T, Pateras IS, Tarcic O, Solomon H, Schetter AJ, Wilder S, Lozano G, Pikarsky E, Forshew T, Rosenfeld N et al. (2013) Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23, 634–646.
68. Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, Piazza S, Rami D, Bulla R, Sommaggio R et al. (2014) Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell 56, 617–629.
69. Weisz L, Damalas A, Liontos M, Karakaidos P, Fontemaggi G, Maor-Aloni R, Kalis M, Levrero M, Strano S, Gorgoulis VG et al. (2007) Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res 67, 2396–2401.
70. Vogel C & Marcotte EM (2012) Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 13, 227–232.
71. Zhang B, Wang J, Wang X, Zhu J, Liu Q, Shi Z, Chambers MC, Zimmerman LJ, Shaddox KF, Kim S et al. (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513, 382–387.
72. Kalo E, Kogan-Sakin I, Solomon H, Bar-Nathan E, Shay M, Shetzer Y, Dekel E, Goldfinger N, Buganim Y, Stambolsky P et al. (2012) Mutant p53R273H attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species. J Cell Sci 125, 5578–5586.
73. Menegon S, Columbano A & Giordano S (2016) The dual roles of NRF2 in cancer. Trends Mol Med 22, 578–593.
74. Trabucchi M, Briata P, Garcia-Mayoral M, Haase AD, Filipowicz W, Ramos A, Gherzi R & Rosenfeld MG (2009) The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature 459, 1010–1014.
75. van Kouwenhove M, Kedde M & Agami R (2011) MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11, 644–656.
76. Lujambio A & Lowe SW (2012) The microcosmos of cancer. Nature 482, 347–355.
77. Kumar MS, Lu J, Mercer KL, Golub TR & Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673–677.
78. Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E et al. (2013) Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol 24, 3082–3088.
79. Zhang Y, Hu Y, Fang JY & Xu J (2016) Gain-of-function miRNA signature by mutant p53 associates with poor cancer outcome. Oncotarget 7, 11056–11066.
80. Garibaldi F, Falcone E, Trisciuoglio D, Colombo T, Lisek K, Walerych D, Del Sal G, Paci P, Bossi G, Piaggio G et al. (2016) Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex. Oncogene 35, 3760–3770.
81. Neilsen PM, Noll JE, Mattiske S, Bracken CP, Gregory PA, Schulz RB, Lim SP, Kumar R, Suetani RJ, Goodall GJ et al. (2013) Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. Oncogene 32, 2992–3000.
82. Subramanian M, Francis P, Bilke S, Li XL, Hara T, Lu X, Jones MF, Walker RL, Zhu Y, Pineda M et al. (2015) A mutant p53/let-7i-axis-regulated gene network drives cell migration, invasion and metastasis. Oncogene 34, 1094–1104.
83. Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S & Blandino G (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19, 1038–1048.
84. Muller PA, Trinidad AG, Caswell PT, Norman JC & Vousden KH (2014) Mutant p53 regulates Dicer through p63-dependent and -independent mechanisms to promote an invasive phenotype. J Biol Chem 289, 122–132.
85. Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A et al. (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30, 3633–3639.
86. Girardini JE, Marotta C & Del Sal G (2014) Disarming mutant p53 oncogenic function. Pharmacol Res 79, 75–87.